
|Videos|January 31, 2019
Overcoming Acquired Resistance Mechanisms in BRAF+ mCRC
Advertisement
Following their discussion on data from the BEACON and ANCHOR trials, experts look towards the future and the potential of overcoming acquired resistance mechanisms in the treatment of BRAF-mutated metastatic colorectal cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Relacorilant Plus Nab-Paclitaxel Meets OS End Point of ROSELLA Trial in PROC
2
NCCN Guidelines Recognize MammaPrint/BluePrint for Determining Anthracycline Benefit in Breast Cancer
3
Unpacking the FDA Approvals That Reshaped Cancer Care in 2025
4
Nogapendekin Alfa Inbakicept Plus NK Cell Therapy Yields Strong OS Signal in Recurrent Glioblastoma
5



































